|
Health and Welfare |
On this page:
Canine Rabies Challenge Study Morris Animal Foundation Studies Dr. Jean Dodds' Vaccination Protocol
Immunology - A Basic Understanding Gene Therapy to Reverse Heart Failure in Animals
Treatment for cardiac hypertrophy Canine Inherited Disorders Database Summertime Warning for Dogs Who Swim
Osteosarcoma phenotype TCR Vaccine for Canine Heart Disease Regenerative Cell (VSRC) therapy
Canine Respiratory Coronavirus and Canine Parvovirus type 2c Zoledronate study
Long-Term Health Risks and Benefits Associated with Spay / Neuter in Dogs
|
|
|
CANINE VACCINATION PROTOCOL – 2007 MINIMAL VACCINE USE NOTE: There is a widely-circulated post that purports to be Dr. Jean Dodds' new vaccination protocol and includes this text, " ... I would like to make you aware that all 27 veterinary schools in North America are in the process of changing their protocols for Vaccinating dogs and cats. Some of this information will present an ethical & economic challenge to Vets, and there will be skeptics." This
is NOT Dr. Dodds' protocol. Please see Dr. Dodd's current
vaccine protocol and article about "Changing Vaccine Protocols"
here. |
from PubMedHeritability and segregation analysis of osteosarcoma in the Scottish deerhound.Phillips JC, Stephenson B, Hauck M, Dillberger J. Department of Small Animal Clinical Sciences, University of Tennessee, Knoxville, TN 37996-4544, USA. Osteosarcoma is the most common malignant bone tumor in dogs and, like its human orthologue, is characterized by aggressive local behavior and high metastatic rates. The Scottish deerhound is a breed of dog with a >15% incidence of osteosarcoma and represents an excellent spontaneously occurring large-animal model of the human disease. We modeled the transmission of the osteosarcoma phenotype in a population of over 1000 related deerhounds ascertained as part of a prospective health study. Variance component analysis, segregation analysis, and linear modeling were performed to evaluate heritability, to infer the presumptive transmission model, and to identify covariate effects for this phenotype within the breed, respectively. Based on variance component analysis, heritability (h(2)) was estimated to be 0.69. Six transmission models were analyzed by segregation analysis; based on Akaike's information criteria, the most parsimonious model was the Mendelian major gene model with dominant expression. Linear modeling identified gender and genotype as significant predictors of disease outcome. Importantly, duration of gonadal hormone exposure, weight, and height at maturity were not significant predictors of outcome. Inheritance of the putative high-risk allele was thus associated with >75% risk of disease occurrence compared to the <5% baseline risk. These results support the hypothesis that a major gene with a dominant effect explains most of the osteosarcoma phenotype within the Scottish deerhound. PMID: 17628392 [PubMed - as supplied by publisher]
|
|
From
PubMed
The Bone Biologic
Effects of Zoledronate in Healthy Dogs
and Dogs with Malignant Osteolysis. Department of Veterinary Clinical Medicine, University of Illinois at Urbana-Champaign, Urbana, IL, USA.
Background: Malignant
osteolysis is a process whereby cancer cells
in concert with osteoclasts erode bone
matrix. Aminobisphosphonates (NBPs) such as
zoledronate induce osteoclast apoptosis and
thereby decrease malignant skeletal
destruction, severity of bone pain, and
frequency of pathologic fracture.
Hypothesis: IV-administered zoledronate will
reduce homeostatic bone turnover in healthy
dogs and pathologic bone resorption in dogs
diagnosed with primary and secondary bone
tumors. Animals: Six healthy dogs and 20
dogs with naturally occurring primary or
metastatic bone tumors were administered
zoledronate IV. Methods: Prospective study:
In all dogs, healthy (n = 6) and with
malignant osteolysis (n = 20), the bone
biologic effects of zoledronate were
evaluated by quantifying changes in serum C-telopeptide
(CTx) or urine N-telopeptide (NTx)
concentrations or both. In dogs with
osteosarcoma (OSA) (n = 10), serial changes
in tumor relative bone mineral density (rBMD)
assessed by dual-energy x-ray absorptiometry
were used to characterize zoledronate's
antiresorptive effects within the immediate
tumor microenvironment. Additionally, the
biochemical tolerability of zoledronate was
assessed in 9 dogs receiving multiple (>/=2)
consecutive treatments.
Results:
All dogs
had significant reductions in serum CTx or
urine NTx concentrations or both after
zoledronate administration. In a subset of
dogs with appendicular OSA, reduced urine
NTx concentrations and increased primary
tumor rBMD coincided with improved limb
usage as reported by pet owners in dogs
treated with zoledronate and concurrent oral
analgesics. Multiple zoledronate infusions
were not associated with biochemical
evidence of toxicosis. Conclusions and
Clinical Importance: In dogs with skeletal
neoplasms, IV-administered zoledronate
exerts bone biologic effects, appears safe,
and can provide pain relief. |
Links to this site do not imply endorsement of any products,
services, organizations,
companies, information providers or content of the
linking site by the IWCA, Inc.
Materials on this and connected pages are the property of the Irish Wolfhound
Club of America
and cannot be reprinted, redistributed or otherwise used without written permission
of the IWCA.
The information on this
site is provided as a public service. Listings of manufacturers,
practitioners, publications, suppliers,
or links to commercial or non-commercial sites do not constitute an
endorsement on our part. There is no implied or
express warrant or guarantee of merchantability or fitness for any
particular usage, application or purpose.
